郑州安图生物工程股份有限公司 外汇套期保值业务管理制度 郑州安图生物工程股份有限公司 第一章 总则 外汇套期保值业务管理制度 第一条 为规范郑州安图生物工程股份有限公司（以下简称"本公司 "或"公司"） 外 汇套期保值业务及相关信息披露工作，加强对外汇套期保值业务的管理，防范投资风险，健全 和完善公司外汇套期保值业务管理机制，确保公司资产安全，根据《中华人民共和国公司法》 《中华人民共和国证券法》《上市公司信息披露管理办法》《上海证券交易所股票上市规则》 《上海证券交易所上市公司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司 自律监管指引第 5 号——交易与关联交易》及《郑州安图生物工程股份有限公司章程》（以 下简称"《公司章程》"）等有关规定，结合公司实际情况，特制定本制度。 （2025 年 10 月制定） 第二条 本制度所称外汇套期保值是指根据公司国际业务的外币收付情况，在金融机构办 理的规避和防范汇率或利率风险的外汇套期保值业务，包括远期结售汇、外汇掉期、外汇期权 、利率互换、利率掉期、利率期权等相关衍生品的单一产品或产品组合，对应基础资产包括利 率、汇率、货币等。既可采取全额交割，也可采 ...

郑州安图生物工程股份有限公司 投资者关系管理制度 郑州安图生物工程股份有限公司 投资者关系管理制度 （2025 年 10 月修订） 第一章 总 则 第一条 为了进一步加强郑州安图生物工程股份有限公司（以下简称"公司"）与投资 者和潜在投资者（以下简称"投资者"）之间的沟通，促进投资者对公司的了解，进一步完 善公司治理结构，实现公司价值最大化和股东利益最大化，切实保护投资者特别是中小投资 者合法权益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司投资者 关系管理工作指引》《上海证券交易所股票上市规则》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》和《公司章程》等有关规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指上市公司通过便利股东权利行使、信息披露、互动交流和 诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对上市公司的了解和 认同，以提升上市公司治理水平和企业整体价值，实现尊重投资者、回报投资者、保护投资 者目的的相关活动。 第三条 投资者关系管理的基本原则是： （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基础上开展， 符合法 ...

Core Viewpoint - Dierui Medical, a leading manufacturer of medical testing instruments and reagents in China, is facing challenges in revenue and profitability, with a significant decline in domestic sales while experiencing growth in overseas markets [2][5][6]. Group 1: Company Overview - Dierui Medical was established on December 26, 1994, and listed on the Shenzhen Stock Exchange on September 10, 2014. The company is headquartered in Changchun, Jilin Province [1]. - The main business of Dierui Medical includes the research, production, and sales of medical testing instruments and supporting reagents, categorized under the pharmaceutical and biological industry, specifically in medical devices and in vitro diagnostics [1]. Group 2: Financial Performance - For Q3 2025, Dierui Medical reported revenue of 469 million yuan, ranking 19th among 39 companies in the industry. The industry leader, New Industries, achieved revenue of 3.428 billion yuan, while the industry average was 708 million yuan [2]. - The net profit for the same period was -87.25 million yuan, placing the company 32nd in the industry. The top performer, Ji'an Medical, reported a net profit of 1.588 billion yuan, with the industry average at 110 million yuan [2]. Group 3: Financial Ratios - As of Q3 2025, Dierui Medical's debt-to-asset ratio was 31.92%, slightly up from 31.73% year-on-year, which is higher than the industry average of 18.29% [3]. - The gross profit margin for Q3 2025 was 33.41%, down from 43.41% in the previous year, and below the industry average of 56.20% [3]. Group 4: Management Team - The chairman, Guo Ting, has extensive experience in the industry, having held various senior positions in pharmaceutical companies. The general manager, Lang Tao, also has a strong background in the pharmaceutical sector [4]. Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 6.48% to 16,800, while the average number of shares held per shareholder increased by 6.92% to 16,200 shares [5]. - The company has seen a decline in domestic sales, with reagent revenue down 22.75% and instrument revenue down 75.97%. However, overseas market revenue increased by 24.02% [5]. Group 6: Market Outlook - The company is adjusting its revenue forecasts for 2025-2026 to 679 million yuan and 720 million yuan, respectively, with a projected net profit of -28 million yuan and 53 million yuan for the same years [5]. - The company is focusing on optimizing its sales structure and expanding its overseas market presence, particularly in Southeast Asia and Belt and Road Initiative countries [6].

Core Viewpoint - Aied Bio, a leading company in the field of tumor precision medical molecular diagnostics in China, has shown strong financial performance and growth potential, with plans for strategic investments to enhance its competitive edge in the industry [1][2][6]. Financial Performance - In Q3 2025, Aied Bio achieved a revenue of 866 million yuan, ranking 12th among 39 companies in the industry, with the industry leader generating 3.428 billion yuan [2]. - The company's net profit for the same period was 263 million yuan, placing it 5th in the industry, while the top performer reported a net profit of 1.588 billion yuan [2]. - The main business revenue composition includes testing reagents at 483 million yuan (83.43%), clinical research services at 56.99 million yuan (9.84%), and testing services at 32.50 million yuan (5.61%) [2]. Financial Ratios - Aied Bio's debt-to-asset ratio stood at 12.79% in Q3 2025, an increase from 11.16% year-on-year, which is lower than the industry average of 18.29%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 83.74%, slightly down from 84.74% year-on-year, but still above the industry average of 56.20%, reflecting robust profitability [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 5.23% to 26,600, while the average number of shares held per shareholder decreased by 4.97% to 14,600 [5]. - The top circulating shareholder, Hong Kong Central Clearing Limited, increased its holdings by 3.53892 million shares [5]. Strategic Investments - The company plans to invest 50 million yuan in Sailu Medical to enhance its upstream sequencing instrument capabilities and improve industry chain collaboration [6]. - Aied Bio anticipates stable overall revenue growth in Q3 2025, with higher growth expected in Q4 due to improved domestic and overseas business conditions [6]. Future Projections - Revenue forecasts for Aied Bio from 2025 to 2027 are projected at 1.239 billion, 1.435 billion, and 1.658 billion yuan, with year-on-year growth rates of 11.73%, 15.83%, and 15.50% respectively [6]. - Expected net profits for the same period are 330 million, 389 million, and 459 million yuan, with growth rates of 29.43%, 17.94%, and 17.96% respectively [6].

Core Insights - 康为世纪 is a leading provider of molecular detection solutions in China, established in 2010 and listed on the Shanghai Stock Exchange in 2022 [1] Financial Performance - In Q3 2025, 康为世纪 reported revenue of 140 million yuan, ranking 36th among 39 companies in the industry, with the industry leader generating 3.428 billion yuan [2] - The company's net profit for the same period was -78.1 million yuan, placing it 31st in the industry, while the top performer reported a net profit of 1.588 billion yuan [2] Profitability and Debt - 康为世纪's debt-to-asset ratio was 9.14% in Q3 2025, lower than the industry average of 18.29% [3] - The gross profit margin for the company was 49.78%, which is below the industry average of 56.20% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.11% to 3,905, while the average number of circulating A-shares held per shareholder increased by 1.13% to 9,729.41 [5] - The largest circulating shareholder, 融通健康产业灵活配置混合A/B, reduced its holdings by 1 million shares [5] Executive Compensation - The chairman and general manager, 王春香, received a salary of 1.205 million yuan in 2024, a decrease of 160,000 yuan from 2023 [4]

Core Viewpoint - Innotec is a leading company in the domestic POCT rapid diagnostic field, particularly strong in respiratory testing with high product accuracy [1] Group 1: Business Performance - In the third quarter of 2025, Innotec reported revenue of 330 million yuan, ranking 20th among 39 companies in the industry [2] - The revenue from the respiratory series was 267 million yuan, accounting for 96.49% of total revenue, while other reagent series contributed 8.27 million yuan (2.99%) and the prenatal series contributed 1.42 million yuan (0.51%) [2] - The net profit for the same period was 131 million yuan, ranking 10th in the industry [2] Group 2: Financial Stability - As of the third quarter of 2025, Innotec's debt-to-asset ratio was 5.76%, lower than the industry average of 18.29%, indicating strong financial stability [3] - The gross profit margin for the period was 78.32%, higher than the industry average of 56.20%, reflecting strong profitability [3] Group 3: Executive Compensation - The chairman, Ye Fengguang, received a salary of 660,700 yuan in 2024, an increase of 366,300 yuan from 2023 [4] - The general manager, Zhang Xiujie, earned 1,578,100 yuan in 2024, up by 217,500 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 10.57% to 8,037 [5] - The average number of circulating A-shares held per shareholder decreased by 8.86% to 8,627.2 [5]

Core Viewpoint - Kehua Bio is a leading company in the in vitro diagnostics sector in China, with a comprehensive product range and a focus on research, production, and sales of various diagnostic reagents and instruments [1] Group 1: Business Performance - In Q3 2025, Kehua Bio reported revenue of 1.191 billion yuan, ranking 7th in the industry out of 39 companies [2] - The company's net profit for the same period was -254 million yuan, placing it last in the industry [2] - The main business composition includes agency products at 395 million yuan (49.76%), self-produced products at 371 million yuan (46.73%), and other revenues at 27.86 million yuan (3.51%) [2] Group 2: Financial Ratios - As of Q3 2025, Kehua Bio's debt-to-asset ratio was 27.53%, an increase from 20.10% in the previous year, exceeding the industry average of 18.29% [3] - The gross profit margin for Q3 2025 was 35.81%, down from 40.04% year-on-year, and below the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and president, Li Ming, received a salary of 2.0822 million yuan in 2024, an increase of 126,600 yuan from 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 13.91% to 48,100 [5] - The average number of circulating A-shares held per shareholder decreased by 12.21% to 10,700 [5] - The sixth largest circulating shareholder is a medical device ETF, which holds 3.1732 million shares as a new shareholder [5]

Core Viewpoint - Zhongyuan Union is a leading enterprise in the domestic cell industry, focusing on cell detection, preparation, storage, and in vitro diagnostics, with a comprehensive and differentiated advantage across the entire industry chain [1] Group 1: Business Performance - In Q3 2025, Zhongyuan Union achieved a revenue of 1.092 billion yuan, ranking 9th among 39 companies in the industry [2] - The company's main business composition includes testing reagents (410 million yuan, 58.46%), cell detection preparation and storage (186 million yuan, 26.49%), scientific research reagents (83.27 million yuan, 11.86%), gene testing (16.87 million yuan, 2.40%), and others (5.53 million yuan, 0.79%) [2] - The net profit for the same period was 99.86 million yuan, ranking 12th in the industry [2] Group 2: Financial Ratios - As of Q3 2025, Zhongyuan Union's asset-liability ratio was 29.26%, down from 30.31% year-on-year, which is higher than the industry average of 18.29% [3] - The company's gross profit margin in Q3 2025 was 69.22%, slightly down from 69.82% year-on-year, but still above the industry average of 56.20% [3] Group 3: Management and Shareholder Structure - The total compensation for General Manager Wang Hongqi was 2.3881 million yuan in 2024, an increase of 1.9688 million yuan compared to 2023 [4] - The controlling shareholder is Shenzhen Jiadao Successful Investment Enterprise (Limited Partnership), with actual controllers Chen Chunmei and Gong Hongjia [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 4.06% to 34,700 [5] - The average number of circulating A-shares held per shareholder decreased by 3.91% to 13,500 [5]

Core Viewpoint - Antu Biology announced the receipt of medical device registration certificates from the National Medical Products Administration and the Henan Provincial Medical Products Administration for the company and its wholly-owned subsidiary, Zhengzhou Sikun Biological Engineering Co., Ltd [2] Group 1 - The announcement was made on the evening of October 30 [2] - The registration certificates are crucial for the company's operations in the medical device sector [2]

Core Viewpoint - 基蛋生物 is a leading company in the in vitro diagnostics sector in China, showcasing significant investment value due to its comprehensive industry chain advantages [1] Group 1: Business Performance - In Q3 2025, 基蛋生物 reported revenue of 758 million yuan, ranking 14th among 39 companies in the industry, with the top company generating 3.428 billion yuan [2] - The company's net profit for the same period was 150 million yuan, placing it 9th in the industry, while the leading company reported a net profit of 1.588 billion yuan [2] - The revenue from self-developed products was 446 million yuan, accounting for 87.08% of total revenue, while other revenue sources contributed 66.22 million yuan, or 12.92% [2] Group 2: Financial Ratios - As of Q3 2025, 基蛋生物's asset-liability ratio was 26.98%, down from 30.26% year-on-year, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.93%, slightly down from 69.43% year-on-year, but still above the industry average of 56.20% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 4.22% to 25,200, while the average number of shares held per shareholder increased by 4.40% to 20,100 [5] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the third largest, holding 12.8725 million shares, an increase of 7.1047 million shares from the previous period [5] Group 4: Executive Compensation - The chairman and general manager, 苏恩本, received a salary of 1.746 million yuan in 2024, which remained unchanged from 2023 [4]